Who invested in Memo Therapeutics

2 rounds we have observed, with the 5 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$24Mraised across 2 rounds since 2015, from 2 sources

$2.3MSeries A$22MSeries C

Latest round: Series C, $22MMay 2024
Step-upi: 9.6×
Investors: 5

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20152017201920212023

$2.3MSeries A$22MSeries C

First round: Series A, $2.3M
Biggest round: $22M
Between rounds: 8.8 years

The rounds

May 2024
Series C$22M2 new1 returning
Source recorded
Jul 2015
Series A$2.3M3 new
From a historical funding record

Founders and team

From Memo Therapeutics's own website: 8 on the team.

Erik van den BergCEO, Board Member
Lars SpengerCFO
Alex BastianVP Commercial Strategy
Kristie ClemmerVP Clinical Operations
Matthieu DelincéVP Technology
Ellen Rietmann AhlNon-Executive Director
Lisanne van KouterikGeneral Counsel
Michael CordesSenior Director Quality Management

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Series A2015Series C2024

Redalpine

Verve Ventures

KurmaPartners

Zürcher Kantonal Bank

EVA Basel

Everyone who backed them

RedalpineVC firm2rounds

Verve VenturesVC firm1round

KurmaPartnersVC firm1round

Zürcher Kantonal BankGovernment1round

EVA BaselVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 3 firms list Memo Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.